Privia Health Group, Inc. Stock Price, News & Analysis

Privia Health (Nasdaq: PRVA) reported strong Q3 2025 results on November 6, 2025: total revenue $580.4M (+32.5% YoY), net income $6.9M (+94.1% YoY) and Adjusted EBITDA $38.2M (+61.6% YoY). Practice Collections rose to $940.4M (+27.1%) and Implemented Providers reached 5,250 (+13.1%).

The company signed a definitive agreement to acquire an ACO business from Evolent for $100M cash plus up to $13M earnout, expected to close in Q4 2025 and expand VBC attributed lives above 1.5M. Cash was $441.4M and no debt at 9/30/25; pro forma cash expected ≈$409.9M after pro forma items. FY'25 guidance was raised above prior high end across key metrics.

Privia Health (Nasdaq: PRVA) said it will report third-quarter and nine-month 2025 financial results before market open on Thursday, November 6, 2025. The press release is expected to be publicly available by 7:00 AM ET on the company's Investor Relations site at ir.priviahealth.com. Management will host a conference call and live webcast at 8:00 AM ET on November 6, 2025 to discuss results and outlook; the webcast will be archived for on-demand replay. Dial-in details for the live call are 888-596-4144 (US) or 646-968-2525 (international) with Conference ID 5704885.

Privia Health (Nasdaq: PRVA) has announced a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health (NYSE: EVH) for $100 million in cash, with an additional performance-based payment of up to $13 million.

The acquisition will add over 120,000 attributed lives through Medicare Shared Savings Program (MSSP), commercial, and Medicare Advantage programs, bringing Privia's total attributed lives in value-based care arrangements to 1.5 million across multiple programs. The deal, expected to close in Q4 2025, will be financed with cash on hand and is projected to contribute positively to Adjusted EBITDA in 2026.

Evolent Health (NYSE: EVH) has announced the sale of its value-based primary care business, Evolent Care Partners (ECP), to Privia Health Group for up to $113 million in cash. The transaction includes $100 million at closing and additional payments in Fall 2026 based on MSSP performance.

The strategic divestiture involves ECP's operations serving over 120,000 members through partnerships with 1,000+ physicians in the Medicare Shared Savings Program. The company plans to use proceeds to prepay senior term debt, expecting to improve annual cash flow by over $7 million.

Evolent reaffirmed its Q3 2025 guidance with revenue of $460-480 million and Adjusted EBITDA of $34-42 million, as well as full-year 2025 outlook of $1.85-1.88 billion in revenue and $140-165 million in Adjusted EBITDA, before accounting for the transaction impact.

Privia Health (Nasdaq: PRVA) has announced exceptional performance in the 2024 Medicare Shared Savings Program, achieving $233.1 million in shared savings, marking a significant 32% increase from 2023. The company's nine Accountable Care Organizations managed $2.5 billion in healthcare benchmark spend through approximately 3,280 providers, serving 194,700 Medicare beneficiaries.

The company's Mid-Atlantic ACO achieved the highest savings rate (10.6%) among ACOs with over 40,000 attributed lives. Notable achievements include beneficiary expenditures 8% lower than median ACO and an impressive aggregate quality score of 89%. Following these strong results, Privia Health has increased its 2025 Adjusted EBITDA guidance to $113-116 million.

Privia Health (Nasdaq: PRVA) reported strong Q2 2025 financial results, with significant growth across key metrics. Total revenue increased 23.4% to $521.2 million, while Practice Collections grew 18.5% to $862.9 million. The company achieved Adjusted EBITDA of $29.0 million, up 31.6% year-over-year.

Notable operational highlights include a 13.8% increase in Implemented Providers to 5,125 and a 15.2% growth in Value-Based Care Attributed Lives to 1.38 million. Following the IMS transaction in Arizona, Privia maintains a strong balance sheet with $390.1 million in cash and no debt.

Based on strong performance, Privia raised its FY2025 guidance above the high end of previous ranges for Practice Collections, GAAP Revenue, Platform Contribution, and Adjusted EBITDA.

Privia Health (Nasdaq: PRVA) has scheduled its second quarter and six-month 2025 financial results announcement for Thursday, August 7, 2025, before market open. The company will release its earnings press release by 7:00 am ET.

Management will host a conference call at 8:00 am ET on the same day to discuss results and future outlook. Investors can access the live webcast through the company's IR website, with replay available after the call. For those joining by phone, the dial-in numbers are 888-596-4144 (domestic) or 646-968-2525 (international) with Conference ID 5704885.

Privia Health (Nasdaq: PRVA) has appointed Lance V. Berberian to its Board of Directors, effective July 15, 2025. Berberian, who will also serve on the Board's Audit Committee, brings over 30 years of technology expertise to the now 10-member board.

Berberian's most recent role was EVP and Chief Information and Technology Officer at Labcorp Holdings, where he led a 5,000-person team focused on IT strategy, cybersecurity, AI, product development, and data management from 2014 to 2024. His prior experience includes CIO positions at IDEXX Laboratories, Kellstrom Aerospace, Interim HealthCare, and Quest Diagnostics.

Privia Health (NASDAQ: PRVA) reported strong Q1 2025 financial results with significant growth across key metrics. Total revenue increased 15.6% to $480.1M, while operating income surged 534% to $5.2M. The company saw net income grow 41.4% to $4.2M. Key operational metrics showed robust performance with Practice Collections up 12.8% to $798.6M and Adjusted EBITDA rising 35.1% to $26.9M. Privia expanded into Arizona through a $95M acquisition of Integrated Medical Services, adding approximately 70 healthcare providers. The company raised its FY2025 guidance to the mid-to-high end of most metrics, maintaining strong growth momentum while expecting minimal increase in value-based shared savings accruals.